Treatment of acute lung injury: Current and emerging pharmacological therapies

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 4, 2013, Pages 487-498

  Sweeney, Robmac ^a   Griffiths, Mark ^b   Mcauley, Danny ^a  

^a Health Sciences Building ^*  (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

acute lung injury; acute respiratory distress syndrome; pharmacotherapy

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; ARACHIDONIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CISATRACURIUM; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCOSAHEXAENOIC ACID; FOOD ADDITIVE; GAMMA LINOLENIC ACID; GLUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; KETOCONAZOLE; LISOFYLLINE; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN; PROTEINASE INHIBITOR; SALBUTAMOL; SELENIUM; SIVELESTAT; SURFACTANT; UNINDEXED DRUG; VASODILATOR AGENT;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; HEART OUTPUT; HUMAN; LUNG COMPLIANCE; LUNG EDEMA; LUNG VASOCONSTRICTION; PHARMACONUTRITION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STEM CELL TRANSPLANTATION; THERAPY; TREATMENT INDICATION; VASODILATATION;

ACUTE LUNG INJURY; ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84881576894     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1351119     Document Type: Article

References (126)

1. Gattinoni L., Pelosi P., Suter P. M., Pedoto A., Vercesi P., Lissoni A. Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care Med: 1998; 158 1 3 11 (Pubitemid 28337150)
2. Gadek J. E., DeMichele S. J., Karlstad M. D., et al. Enteral Nutrition in ARDS Study Group Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med: 1999; 27 8 1409 1420 (Pubitemid 29406926)
3. Pacht E. R., DeMichele S. J., Nelson J. L., Hart J., Wennberg A. K., Gadek J. E. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med: 2003; 31 2 491 500 (Pubitemid 36232946)
4. Pontes-Arruda A., Aragão A. MA, Albuquerque J. D. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med: 2006; 34 9 2325 2333 (Pubitemid 44260016)
5. Singer P., Theilla M., Fisher H., Gibstein L., Grozovski E., Cohen J. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med: 2006; 34 4 1033 1038
6. Marik P. E., Zaloga G. P. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med: 2008; 34 11 1980 1990
7. Rice T. W., Wheeler A. P., Thompson B. T., deBoisblanc B. P., Steingrub J., Rock P. NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators Enteral omega-3 fatty acid, γ-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA: 2011; 306 14 1574 1581
8. Stapleton R. D., Martin T. R., Weiss N. S., et al. A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury. Crit Care Med: 2011; 39 7 1655 1662
9. Cook D. J., Heyland D. K. Pharmaconutrition in acute lung injury. JAMA: 2011; 306 14 1599 1600
10. Pacht E. R., Timerman A. P., Lykens M. G., Merola A. J. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest: 1991; 100 5 1397 1403
11. Bernard G. R., Wheeler A. P., Arons M. M., et al. The Antioxidant in ARDS Study Group A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest: 1997; 112 1 164 172 (Pubitemid 27343614)
12. Ortolani O., Conti A., De Gaudio A. R., Masoni M., Novelli G. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock: 2000; 13 1 14 18
13. Jepsen S., Herlevsen P., Knudsen P., Bud M. I., Klausen N. O. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med: 1992; 20 7 819 923
14. Suter P. M., Domenighetti G., Schaller M. D., Laverrière M. C., Ritz R., Perret C. N-acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest: 1994; 105 1 190 194 (Pubitemid 24029100)
15. Domenighetti G., Suter P. M., Schaller M-D, Ritz R., Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care: 1997; 12 4 177 182 (Pubitemid 28051043)
16. Montravers P., Fagon J. Y., Gilbert C., Blanchet F., Novara A., Chastre J. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest: 1993; 103 4 1017 1022 (Pubitemid 23110263)
17. The Acute Respiratory Disease Syndrome Network Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med: 2002; 30 1 1 6
18. Moraes T. J., Chow C. W., Downey G. P. Proteases and lung injury. Crit Care Med: 2003; 31 (4, Suppl): S189 S194 (Pubitemid 36458166)
19. Tamakuma S., Shiba T., Hirasawa H., et al. A phase III clinical study of neutrophil elastase inhibitor ONO-5046 Na in SIRS patients. J Clin Ther Med (Japan): 1998; 14 289 318
20. Zeiher B. G., Artigas A., Vincent J. L., et al. STRIVE Study Group Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med: 2004; 32 8 1695 1702 (Pubitemid 39050520)
21. Iwata K., Doi A., Ohji G., et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med: 2010; 49 22 2423 2432
22. Slotman G. J., Burchard K. W., D'Arezzo A., Gann D. S. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma: 1988; 28 5 648 654
23. The ARDS Network Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA: 2000; 283 15 1995 2002
24. Rosenberg A. L., Dechert R. E., Park P. K., Bartlett R. H. The National Heart L, Blood Institute ARDSCTN. Review of A Large Clinical Series: Association of Cumulative Fluid Balance on Outcome in Acute Lung Injury: A Retrospective Review of the ARDSnet Tidal Volume Study Cohort. J Intensive Care Med: 2009; 24 1 35 46
25. Sakr Y., Vincent J-L, Reinhart K., et al. Sepsis Occurence in Acutely Ill Patients Investigators High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest: 2005; 128 5 3098 3108 (Pubitemid 41698628)
26. Davey-Quinn A., Gedney J. A., Whiteley S. M., Bellamy M. C. Extravascular lung water and acute respiratory distress syndrome-oxygenation and outcome. Anaesth Intensive Care: 1999; 27 4 357 362 (Pubitemid 29396524)
27. Humphrey H., Hall J., Sznajder I., Silverstein M., Wood L. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest: 1990; 97 5 1176 1180 (Pubitemid 20166812)
28. Wiedemann H. P., Wheeler A. P., Bernard G. R., et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network Comparison of two fluid-management strategies in acute lung injury. N Engl J Med: 2006; 354 24 2564 2575 (Pubitemid 43882352)
29. Perkins G. D., McAuley D. F., Richter A., Thickett D. R., Gao F. Bench-to-bedside review: beta2-agonists and the acute respiratory distress syndrome. Crit Care: 2004; 8 1 25 32 (Pubitemid 38195567)
30. Wright P. E., Carmichael L. C., Bernard G. R. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest: 1994; 106 5 1517 1523 (Pubitemid 24346121)
31. Pesenti A., Pelosi P., Rossi N., Aprigliano M., Brazzi L., Fumagalli R. Respiratory mechanics and bronchodilator responsiveness in patients with the adult respiratory distress syndrome. Crit Care Med: 1993; 21 1 78 83 (Pubitemid 23028479)
32. Moriña P., Herrera M., Venegas J., Mora D., Rodríguez M., Pino E. Effects of nebulized salbutamol on respiratory mechanics in adult respiratory distress syndrome. Intensive Care Med: 1997; 23 1 58 64 (Pubitemid 27067897)
33. Perkins G. D., McAuley D. F., Thickett D. R., Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med: 2006; 173 3 281 287 (Pubitemid 43209082)
34. Basran G. S., Hardy J. G., Woo S. P., Ramasubramanian R., Byrne A. J. Beta-2-adrenoceptor agonists as inhibitors of lung vascular permeability to radiolabelled transferrin in the adult respiratory distress syndrome in man. Eur J Nucl Med: 1986; 12 8 381 384 (Pubitemid 17041307)
35. Licker M., Tschopp J-M, Robert J., Frey J-G, Diaper J., Ellenberger C. Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest: 2008; 133 4 845 852 (Pubitemid 351536857)
36. Manocha S., Gordon A. C., Salehifar E., Groshaus H., Walley K. R., Russell J. A. Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. Crit Care: 2006; 10 1 R12
37. 2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med: 2011; 184 5 561 568
38. Gao Smith F., Perkins G. D., Gates S., et al. BALTI-2 study investigators Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet: 2012; 379 9812 229 235
39. Bassford C. R., Thickett D. R., Perkins G. D. The rise and fall of β-agonists in the treatment of ARDS. Crit Care: 2012; 16 2 208
40. Price L. C., McAuley D. F., Marino P. S., Finney S. J., Griffiths M. J., Wort S. J. Pathophysiology of pulmonary hypertension in acute lung injury. Am J Physiol Lung Cell Mol Physiol: 2012; 302 9 L803 L815
41. Siobal M. S., Hess D. R. Are inhaled vasodilators useful in acute lung injury and acute respiratory distress syndrome? Respir Care: 2010; 55 2 144 157, discussion 157-161
42. Lowson S. M. Alternatives to nitric oxide. Br Med Bull: 2004; 70 1 119 131 (Pubitemid 40069376)
43. Cuthbertson B. H., Galley H. F., Webster N. R. Effect of inhaled nitric oxide on key mediators of the inflammatory response in patients with acute lung injury. Crit Care Med: 2000; 28 6 1736 1741 (Pubitemid 30428721)
44. Day R. W., Allen E. M., Witte M. KA. A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure. Chest: 1997; 112 5 1324 1331 (Pubitemid 27497867)
45. Dellinger R. P., Zimmerman J. L., Taylor R. W., et al. Inhaled Nitric Oxide in ARDS Study Group Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med: 1998; 26 1 15 23 (Pubitemid 28028435)
46. Dobyns E. L., Cornfield D. N., Anas N. G., et al. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr: 1999; 134 4 406 412 (Pubitemid 30180620)
47. Gerlach H., Keh D., Semmerow A., et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med: 2003; 167 7 1008 1015 (Pubitemid 36408167)
48. Lundin S., Mang H., Smithies M., Stenqvist O., Frostell C. The European Study Group of Inhaled Nitric Oxide Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Intensive Care Med: 1999; 25 9 911 919 (Pubitemid 29452535)
49. Mehta S., Simms H., Levy M., et al. Inhaled nitric oxide improves oxygenation acutely but not chronically in acute respiratory distress syndrome: a randomized, controlled trial. Journal of Applied Research: 2001; 1 2 73 84
50. Michael J. R., Barton R. G., Saffle J. R., et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med: 1998; 157 5 Pt 1 1372 1380
51. Park K. J., Lee Y. J., Oh Y. J., Lee K. S., Sheen S. S., Hwang S. C. Combined effects of inhaled nitric oxide and a recruitment maneuver in patients with acute respiratory distress syndrome. Yonsei Med J: 2003; 44 2 219 226 (Pubitemid 36592183)
52. Taylor R. W., Zimmerman J. L., Dellinger R. P., et al. Inhaled Nitric Oxide in ARDS Study Group Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA: 2004; 291 13 1603 1609 (Pubitemid 38552433)
53. Angus D. C., Clermont G., Linde-Zwirble W. T., et al. NO-06 Investigators Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a phase III trial of inhaled nitric oxide. Crit Care Med: 2006; 34 12 2883 2890 (Pubitemid 44808728)
54. Troncy E., Collet J-P, Shapiro S., et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med: 1998; 157 5 Pt 1 1483 1488
55. Creagh-Brown B. C., Griffiths M. J., Evans T. W. Bench-to-bedside review: inhaled nitric oxide therapy in adults. Crit Care: 2009; 13 3 221
56. Sokol J., Jacobs S. E., Bohn D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth Analg: 2003; 97 4 989 998 (Pubitemid 37158678)
57. Adhikari N. KJ, Burns K. EA, Friedrich J. O., Granton J. T., Cook D. J., Meade M. O. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ: 2007; 334 7597 779
58. Afshari A., Brok J., Moller A. M., Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth Analg: 2011; 112 6 1411 1421
59. Dahlem P., van Aalderen W. M., de Neef M., Dijkgraaf M. G., Bos A. P. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med: 2004; 32 4 1055 1060 (Pubitemid 38471530)
60. Zwissler B., Kemming G., Habler O., et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med: 1996; 154 6 Pt 1 1671 1677 (Pubitemid 26424933)
61. Walmrath D., Schneider T., Schermuly R., Olschewski H., Grimminger F., Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med: 1996; 153 3 991 996 (Pubitemid 26081651)
62. Van Heerden P. V., Blythe D., Webb S. A. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS-a pilot study. Anaesth Intensive Care: 1996; 24 5 564 568 (Pubitemid 26377305)
63. Holcroft J. W., Vassar M. J., Weber C. J. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann Surg: 1986; 203 4 371 378 (Pubitemid 16056758)
64. Bone R. C., Slotman G., Maunder R., et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest: 1989; 96 1 114 119 (Pubitemid 19176426)
65. Rossignon M. D., Khayat D., Royer C., Rouby J. J., Jacquillat C., Viars P. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double-blind placebo-controlled study on the activity of prostaglandin E1. Anesthesiology: 1990; 72 2 276 281 (Pubitemid 20057994)
66. Abraham E., Baughman R., Fletcher E., et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med: 1999; 27 8 1478 1485 (Pubitemid 29406936)
67. Vincent J. L., Brase R., Santman F., et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med: 2001; 27 10 1578 1583 (Pubitemid 33027953)
68. Reyes A., Roca J., Rodriguez-Roisin R., Torres A., Ussetti P., Wagner P. D. Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis: 1988; 137 5 1062 1067
69. Gallart L., Lu Q. IN, Puybasset L., Umamaheswara Rao G. S., Coriat P., Rouby J. J. The NO Almitrine Study Group Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. Am J Respir Crit Care Med: 1998; 158 6 1770 1777 (Pubitemid 29008813)
70. Wysocki M., Delclaux C., Roupie E., et al. Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Intensive Care Med: 1994; 20 4 254 259 (Pubitemid 24132364)
71. Liu K. D., Levitt J., Zhuo H., et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med: 2008; 178 6 618 623
72. Ranieri V. M., Thompson B. T., Barie P. S., et al. PROWESS-SHOCK Study Group Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med: 2012; 366 22 2055 2064
73. Miller A. C., Rivero A., Ziad S., Smith D. J., Elamin E. M. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res: 2009; 30 2 249 256
74. Dixon B., Santamaria J. D., Campbell D. J. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care: 2008; 12 3 R64
75. Dixon B., Schultz M. J., Hofstra J. J., Campbell D. J., Santamaria J. D. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care: 2010; 14 5 445
76. Dixon B., Schultz M. J., Smith R., Fink J. B., Santamaria J. D., Campbell D. J. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care: 2010; 14 5 R180
77. Laterre P. F., Wittebole X., Dhainaut J. F. Anticoagulant therapy in acute lung injury. Crit Care Med: 2003; 31 (4, Suppl): S329 S336 (Pubitemid 36458188)
78. MacLaren R., Stringer K. A. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy: 2007; 27 6 860 873 (Pubitemid 46849430)
79. Nieuwenhuizen L., de Groot P. G., Grutters J. C., Biesma D. H. A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia. Eur J Haematol: 2009; 82 6 413 425
80. Tuinman P. R., Dixon B., Levi M., Juffermans N. P., Schultz M. J. Nebulized anticoagulants for acute lung injury: a systematic review of preclinical and clinical investigations. Crit Care: 2012; 16 2 R70
81. Raoof S., Goulet K., Esan A., Hess D. R., Sessler C. N. Severe hypoxemic respiratory failure, II: Nonventilatory strategies. Chest: 2010; 137 6 1437 1448
82. Warr J., Thiboutot Z., Rose L., Mehta S., Burry L. D. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. Ann Pharmacother: 2011; 45 9 1116 1126
83. Forel J-M, Roch A., Marin V., et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med: 2006; 34 11 2749 2757 (Pubitemid 44610939)
84. Deem S., Lee C. M., Curtis J. R. Acquired neuromuscular disorders in the intensive care unit. Am J Respir Crit Care Med: 2003; 168 7 735 739 (Pubitemid 37188296)
85. Hermans G., De Jonghe B., Bruyninckx F., Van den Berghe G. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care: 2008; 12 6 238
86. Arroliga A., Frutos-Vivar F., Hall J., et al. International Mechanical Ventilation Study Group Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest: 2005; 128 2 496 506 (Pubitemid 41140473)
87. Gainnier M., Roch A., Forel J-M., et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med: 2004; 32 1 113 119 (Pubitemid 38125571)
88. Papazian L., Forel J-M, Gacouin A., et al. ACURASYS Study Investigators Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med: 2010; 363 12 1107 1116
89. Rudis M. I., Sikora C. A., Angus E., et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med: 1997; 25 4 575 583 (Pubitemid 27193968)
90. Frerking I., Günther A., Seeger W., Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med: 2001; 27 11 1699 1717 (Pubitemid 33139831)
91. Kesecioglu J., Schultz M., Lundberg D., Lauven P., Assael B. M. Treatment of acute lung injury (ALI/ARDS) with surfactant [abstract]. Am J Respir Crit Care Med: 2001; 163 A819
92. Kesecioglu J., Schultz M., Maas J., De Wilde R., Steenken E., Lachmann B. Treatment of acute lung injury and ARDS with surfactant is safe [abstract]. Am J Respir Crit Care Med: 2004; 169 A349
93. Kesecioglu J., Beale R., Stewart T. E., et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med: 2009; 180 10 989 994
94. Spragg R. G., Lewis J. F., Wurst W., et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med: 2003; 167 11 1562 1566 (Pubitemid 37363368)
95. Anzueto A., Baughman R. P., Guntupalli K. K., et al. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med: 1996; 334 22 1417 1421 (Pubitemid 26157436)
96. Spragg R. G., Lewis J. F., Walmrath H-D., et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med: 2004; 351 9 884 892
97. Spragg R. G., Taut F. JH, Lewis J. F., et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med: 2011; 183 8 1055 1061
98. Davidson W. J., Dorscheid D., Spragg R. G., Schulzer M., Mak E., Ayas N. T. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care: 2006; 10 2 R41
99. Stevens T. P., Sinkin R. A. Surfactant replacement therapy. Chest: 2007; 131 5 1577 1582 (Pubitemid 46762371)
100. Craig T., O'Kane C. M., McAuley D. F. Potential mechanisms by which statins modulate pathogenic mechanisms important in the development of acute lung injury. In: Vincent J. L. ed. 27th Yearbook of Intensive Care and Emergency Medicine. Berlin, Germany Springer-Verlag: 2007; 287 300
101. Chalmers J. D., Short P. M., Mandal P., Akram A. R., Hill A. T. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med: 2010; 104 8 1081 1091
102. Kor D. J., Iscimen R., Yilmaz M., Brown M. J., Brown D. R., Gajic O. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med: 2009; 35 6 1039 1046
103. Irish Critical Care Trials Group Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care: 2008; 12 1 R30
104. Bajwa E. K., Malhotra C. K., Thompson B. T., Christiani D. C., Gong M. N. Statin therapy as prevention against development of acute respiratory distress syndrome: an observational study. Crit Care Med: 2012; 40 5 1470 1477
105. O'Neal H. RJ Jr, Koyama T., Koehler E. AS., et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med: 2011; 39 6 1343 1350
106. Shyamsundar M., McKeown S. T., O'Kane C. M., et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med: 2009; 179 12 1107 1114
107. Honiden S., Gong M. N. Diabetes, insulin, and development of acute lung injury. Crit Care Med: 2009; 37 8 2455 2464
108. Donnelly M., Condron C., Murray P., Bouchier-Hayes D. Modulation of the glycemic response using insulin attenuates the pulmonary response in an animal trauma model. J Trauma: 2007; 63 2 351 357 (Pubitemid 47254646)
109. Chen H. I., Yeh D. Y., Liou H-L, Kao S-J. Insulin attenuates endotoxin-induced acute lung injury in conscious rats. Crit Care Med: 2006; 34 3 758 764
110. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med: 2001; 345 19 1359 1367
111. Kuba K., Imai Y., Rao S., et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med: 2005; 11 8 875 879 (Pubitemid 41161120)
112. Imai Y., Kuba K., Penninger J. M. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol: 2008; 93 5 543 548 (Pubitemid 351595063)
113. Marshall R. P., Webb S., Bellingan G. J., et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med: 2002; 166 5 646 650 (Pubitemid 34971844)
114. Jerng J-S, Yu C-J, Wang H-C, Chen K-Y, Cheng S-L, Yang P-C. Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med: 2006; 34 4 1001 1006
115. Orfanos S. E., Armaganidis A., Glynos C., et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation: 2000; 102 16 2011 2018
116. Imai Y., Kuba K., Rao S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature: 2005; 436 7047 112 116 (Pubitemid 40966195)
117. Hofstra J. J., Levi M., Schultz M. J. HETRASE study-did heparin treatment benefit patients with ALI/ARDS? Crit Care Med: 2009; 37 8 2490
118. Noto M. J., Wheeler A. P. Macrolides for acute lung injury. Chest: 2012; 141 5 1131 1132
119. Walkey A. J., Wiener R. S. Macrolide antibiotics and survival in patients with acute lung injury. Chest: 2012; 141 5 1153 1159
120. Matthay M. A. Advances and challenges in translating stem cell therapies for clinical diseases. Transl Res: 2010; 156 3 107 111
121. van Poll D., Parekkadan B., Borel Rinkes I. H., Tilles A. W., Yarmush M. L. Mesenchymal stem cell therapy for protection and repair of injured vital organs. Cell Mol Bioeng: 2008; 1 1 42 50
122. Gupta N., Krasnodembskaya A., Kapetanaki M., et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax: 2012; 67 6 533 539
123. Curley G. F., Hayes M., Ansari B., et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax: 2012; 67 6 496 501
124. Mac Sweeney R., McAuley D. F. Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial? Thorax: 2012; 67 6 475 476
125. Paine R. I. III, Standiford T. J., Dechert R. E., et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med: 2012; 40 1 90 97
126. Qian L., Huang Y., Spencer C. I., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature: 2012; 485 7400 593 598